AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11919661
Drug: Buprenorphine 4
RxNorm normalized name: buprenorphine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 4 mg/placebo on alternating days
Trial: 11919661
Drug: Buprenorphine 32
RxNorm normalized name: BUPRENORPHINE 32MG/0.64ML SA INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 32 mg/placebo on alternating days
Trial: 11919661
Drug: High-dose buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose buprenorphine (regardless of schedule)
Trial: 835509
Drug: Iron-fortified grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified grain products daily for 6 to 8 months
Trial: 835509
Drug: Daily ferrous
RxNorm normalized name: Ferrous Fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily ferrous sulfate administration for those with hemoglobin levels below 13 g/dl
Trial: 2430506
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine combined with oral penicillin-V (twice daily)
Trial: 2430506
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine combined with benzathine penicillin (intramuscularly every 4 weeks)
Trial: 24745701
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen sublingual immunotherapy
Trial: 23444750
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with antioxidant agents containing alpha lipoic acid (ALA) plus calcium and vitamin D3 (n = 25)
Trial: 16218969
Drug: Intra-oral injection
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-oral injection of ketorolac (30 mg in 1 mL)
Trial: 11872034
Drug: Apomorphine SL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine SL (2 mg for 2 weeks, then 3 mg for 2 weeks, and finally 4 mg for the remaining 4 weeks)
Trial: 9989366
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg od)
Trial: 7787438
Drug: Adjunctive antithyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antithyroid drugs (ATD) in a form of block‐replacement regimen of methimazole (MMI) plus L‐T4 for 6 months
Trial: 7787438
Drug: Radioiodine (RAI)
RxNorm normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine (RAI) therapy alone
Trial: 2370643
Drug: Dilevalol (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (acute and chronic treatment)
Trial: 31991296
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (1500 mg, three times per day) for 3 months
Trial: 17081532
Drug: Postoperative triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative triptorelin treatment
Trial: 16251373
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise (weekly exercise class consisting of light aerobic exercise, muscle strengthening and stretching for 6 months)
Trial: 1918559
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (CT)
Trial: 1918559
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CO)
Trial: 25800041
Drug: Adjuvant intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant intra-arterial chemotherapy (IAC) and concomitant radiotherapy (RT)
Trial: 22492368
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL red orange juice/d
Trial: 22492368
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL placebo/d
Trial: 2039045
Drug: Preoperative 0.03%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative 0.03% flurbiprofen every 30 minutes for four doses
Trial: 6981162
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of two double-strength trimethoprim-sulfamethoxazole (TMP-SMZ) tablets (320 mg of TMP and 1,600 mg of SMZ)
Trial: 6981162
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy of one double-strength tablet (160 mg of TMP and 800 mg of SMZ) twice a day for 10 days
Trial: 26329939
Drug: Topical Tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tacrolimus 0.03% twice daily for three weeks
Trial: 17313301
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g L-carnitine L-tartrate
Trial: 17313301
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g L-carnitine L-tartrate
Trial: 17313301
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g L-carnitine L-tartrate (control)
Trial: 17055209
Drug: Madopar (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar (200 mg levodopa and 50 mg benserazide)
Trial: 15687727
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (injection) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Trial: 15687727
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (infusion) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Trial: 15687727
Drug: Oral esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole 40 mg once daily for 4 weeks
Trial: 8233728
Drug: High caloric
RxNorm normalized name: high caloric supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High caloric supplement (500 kcal/d)
Trial: 8233728
Drug: Low caloric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low caloric supplement (140 kcal/d)
Trial: 3898976
Drug: Pivampicillin 700
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin 700 mg twice daily for 6 days
Trial: 25794603
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dabrafenib and trametinib
Trial: 15226337
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated cranial radiation therapy (CFX)
Trial: 15226337
Drug: Hyperfractionated cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated cranial radiation therapy (HFX)
Trial: 11477497
Drug: 4.2 g
RxNorm normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 g CLA/day
Trial: 7822600
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral thermometry (CRAFTEMP)
Trial: 7822600
Drug: Optimum oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum oral thermometry (TERUMO WCT)
Trial: 7822600
Drug: Routine rectal
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine rectal thermometry (TERUMO WCT)
Trial: 7822600
Drug: Optimum rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum rectal thermometry (TERUMO WCT)
Trial: 3168766
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexamethasone
Trial: 18071344
Drug: Habit-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit-based intervention (n=69, with subgroups of n=33 for weekly weighing and n=36 for monthly weighing)
Trial: 9346982
Drug: Three new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three new topical anesthetics (prilocaine-phenylephrine, tetracaine-phenylephrine, tetracaine-lidocaine-phenylephrine)
Trial: 8478305
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg orally once daily)
Trial: 8478305
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg orally qds)
Trial: 3006464
Drug: diatrizoate (ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diatrizoate (ionic radiographic contrast agent)
Trial: 3006464
Drug: iopamidol (nonionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol (nonionic radiographic contrast agent)
Trial: 30518693
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg) + Saline
Trial: 30518693
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo Metformin
Trial: 25562774
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention (usual care plus pharmaceutical care)
Trial: 18236371
Drug: prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone acetate 1 % eye drops 5 x /day, tapering off by one drop every month
Trial: 16487668
Drug: Prison methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prison methadone treatment
Trial: 14723479
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patch therapy (n = 2)
Trial: 14723479
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch therapy (n = 4)
Trial: 20533241
Drug: GPLC (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPLC (4.5 g/day)
Trial: 10630656
Drug: Age adjusted
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age adjusted warfarin loading protocol
Trial: 10630656
Drug: Empirical dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical dosing
Trial: 1666684
Drug: High-dose naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naloxone (10 mg bolus plus 7 mg/hr)
Trial: 6462107
Drug: Gentamicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin alone (2 mg/kg IV)
Trial: 6462107
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with carbenicillin (2 g IV every 8 h for six doses)
Trial: 6462107
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with piperacillin (4 g IV every 12 h for four doses)
Trial: 3840740
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (4 mg preservative-free morphine in 6 ml saline)
Trial: 3840740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anaesthetised without intrathecal morphine)
Trial: 25772920
Drug: Re-wetting agent
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-wetting agent with 37% phosphoric acid etching
Trial: 25772920
Drug: Re-wetting agent
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-wetting agent with Erbium: Yttrium aluminium garnet laser etching
Trial: 16573545
Drug: Thymoglobulin induction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin induction, rapamycin (RAPA), and immunonutrients (arginine and omega-3 fatty acids); Mycophenolate mofetil (MMF) started in standard doses and discontinued by 2 years; CsA given in reduced doses for either 4, 6, or 12 months.
Trial: 10715225
Drug: Sorbitol 40
RxNorm normalized name: sorbitol 40 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol 40 g/day in candy
Trial: 10715225
Drug: Olestra 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 20 g/day in potato chips
Trial: 10715225
Drug: Olestra 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 40 g/day in potato chips
Trial: 8268900
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine, possibly with a converting-enzyme inhibitor and a thiazide)
Trial: 3082592
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethisterone acetate + 50 micrograms ethinyloestradiol (NA 1 + EE 50)
Trial: 24397906
Drug: MenACWY-CRM plus
RxNorm normalized name: hydrocortisone Rectal Cream [Recort Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM plus routine vaccines
Trial: 24220326
Drug: Routine vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vaccines alone
Trial: 18544424
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 270 microg/kg rFVIIa
Trial: 18544424
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment schedules (multiple bolus doses of 90 to 120 microg/kg every 2 to 3 hours)
Trial: 9013369
Drug: Codeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (60 mg administered orally)
Trial: 1568521
Drug: Intra-articular rifamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular rifamycin SV (525 mg/week) for 10 weeks
Trial: 1568521
Drug: Auranofin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (3 mg orally twice daily)
Trial: 31763263
Drug: Nasya +
RxNorm normalized name: Hyaluronic acid (NASHA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasya + Oral Group
Trial: 28371482
Drug: 1% brinzolamide/0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% brinzolamide/0.5% timolol fixed combination (BTFC)
Trial: 28371482
Drug: 1% dorzolamide/0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% dorzolamide/0.5% timolol fixed combination (DTFC)
Trial: 25265147
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 μg/kg) and thiopental sodium (4 mg/kg)
Trial: 25265147
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium (3 mg/kg, placebo)
Trial: 21693655
Drug: Doxorubicin (60,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide with paclitaxel
Trial: 21693655
Drug: Doxorubicin (60,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide without paclitaxel
Trial: 12650957
Drug: mianserin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (15 mg/day)
Trial: 11019421
Drug: L-arginine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (15 g/day for 10 days)
Trial: 3880810
Drug: Survival by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survival by treatment
Trial: 3880810
Drug: Complications of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complications of therapy
Trial: 23241505
Drug: IL-2 plus
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 plus LMI vaccine
Trial: 9071621
Drug: Terbinafine 125
RxNorm normalized name: terbinafine 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 125 mg orally twice daily for 4 weeks (Group 1, ages 5-15)
Trial: 9071621
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg orally twice daily for 4 weeks (Group 2, ages > 15)
Trial: 7361797
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1 g four times daily)
Trial: 30550828
Drug: Tezepelumab 280
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab 280 mg plus class 3 topical corticosteroids (TCS)
Trial: 30550828
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus class 3 topical corticosteroids (TCS)
Trial: 23336594
Drug: MYO 2
RxNorm normalized name: Nymyo 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYO 2 g plus folic acid 200 mg every day
Trial: 23336594
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 200 mg every day
Trial: 17347063
Drug: ZOL 5
RxNorm normalized name: danazol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOL 5 mg
Trial: 17347063
Drug: ALN 70
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN 70 mg
Trial: 8373713
Drug: Zolpidem (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (5 and 10 mg) after seven nightly doses
Trial: 8373713
Drug: Nightly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nightly administration of zolpidem
Trial: 28027368
Drug: Friendship Bench
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friendship Bench intervention (6 sessions of individual problem-solving therapy delivered by trained, supervised lay health workers plus an optional 6-session peer support program)
Trial: 19631948
Drug: Fluoxetine 20mg
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20mg and Venlafaxine 150mg
Trial: 18586659
Drug: Telavancin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin 7.5 mg/kg
Trial: 18586659
Drug: Telavancin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin 15 mg/kg
Trial: 16028436
Drug: 12-week physical
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week physical activity programme (30 min of brisk walking and a daily 11-min home-based programme)
Trial: 12503699
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled 10 min before mannitol
Trial: 12503699
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled 5 min after mannitol
Trial: 12503699
Drug: Terbutaline inhaled
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhaled 10 min before the control for mannitol
Trial: 10519734
Drug: Simvastatin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (mean dose 28.6 mg/day)
Trial: 10519734
Drug: Cholestyramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (mean dose 19.3 g/day)
Trial: 7734901
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 20 mg/kg
Trial: 31286118
Drug: Glycine air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine air polishing (G)
Trial: 28500784
Drug: DL‐PDT (Daylight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL‐PDT (Daylight Photodynamic Therapy)
Trial: 21075536
Drug: Octenidine-Gel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine-Gel®
Trial: 19776406
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin (90 mg/m²) plus cytarabine (100 mg/m²)
Trial: 19776406
Drug: Standard-dose daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose daunorubicin (45 mg/m²) plus cytarabine (100 mg/m²)
Trial: 17598694
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of topiramate (25 mg)
Trial: 17598694
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of topiramate (25 mg)
Trial: 11303823
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (OD) gentamicin dosing
Trial: 11303823
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily (TD) gentamicin dosing
Trial: 9600579
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg oral m-CPP
Trial: 9600579
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg oral m-CPP (females only)
Trial: 7992274
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with Elmedistraal
Trial: 23618609
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (SC group) with fentanyl
Trial: 23618609
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (SC group)
Trial: 17219967
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Triptorelin (3.75 mg) at 6-week intervals